Try $250,600,000.00!!! From their 10K: "Our net loss for the years ended December 31, 2010, 2009 and 2008 was $15.5 million, $38.8 million
and $25.4 million, respectively. As of December 31, 2010 and 2009, our accumulated deficit was $250.6 million and $235.0 million, respectively. We may never generate sufficient net revenue to achieve or sustain profitability."
Congratulations to Tally and the team for running one of the biggest scams ever on Wall Street.
1 week after 18th dilution and a reverse split - Lars clown still thinks
managment is doing great hahahah
After 7 years of Jack "ah eh liar" Talley - where are the revenues ?
And where is the NP1 partner and the big upfront ? Talleys next great IDIS deal ?
Want me to post your past "PREDICTIONS" ? hahahahaha
Lars - how much do you get Talley lover ?
See ya next dilution when you pay Talleys salary again....
Products are worth what they bring in the market or get from partners. Ceplene: insignificant and NP-1 since years no partner, that's all. This clown mgmt. created huge losses for “general purposes”, what means for their personal income. Trolls, but not stockholders, find that smart.
So, please, give us your calculation of the fair price of having these two drugs up to the level where Ceplene and NP-1 are now. Less than 250 millions?
Was it wrong or not to buy Maxim and the NP-1 rights? Do you find the price high or a smart deal?
Give us some reasonable answers before your manner of giving persons names.
Unfortunately this is true: Talley's only long-term „contributions“ consist of selling shares below the market value and of failures in every technical project. That way this person has created a 90% decline of the compay value.
An accumulation of these huge company losses could also be easily reached by employing any illiterate on the street. Therefore such “operating results” do not need such kind of “qualified” CEO with a million salary.
250 millions is that the total cost for having an approved cancer drug in the EU a n d a pain drug having excellent results in phase IIb for more than a 1000 million USD market? Results out in May for NP-1.
I have just been here for some 2.5 years, after the EU-approval. Remember Epicept bought Ceplene via "Maxim" for a cheap price.
It's all about your view upon the possible markets for the portefolio. If you do not share the outlook, or management work, use your time more rational.
Clicking on your earlier messages tells a story.